Search for: "AMGEN INC."
Results 501 - 520
of 707
Sort by Relevance
|
Sort by Date
22 Nov 2011, 9:24 am
Amgen Inc., No. 09-56965, 2011 U.S. [read post]
18 Nov 2011, 6:58 am
Amgen et al., it was also the basis for a securities lawsuit alleging that a retirement investor was misled by public statements made by Amgen Inc. and four of its officers about the anemia drugs Aranesp and Epogen. [read post]
16 Nov 2011, 5:00 am
Amgen Inc., ___ F.3d ___ (9th Cir. [read post]
14 Nov 2011, 4:21 pm
Amgen, Inc., the plaintiff alleged that misstatements and failure to disclose by defendants illegally inflated the value of Amgen stock. [read post]
11 Nov 2011, 3:04 pm
By way of background, Amgen, Inc. [read post]
9 Nov 2011, 8:45 pm
Amgen Inc., No. 09-56965 (9th Cir. [read post]
25 Oct 2011, 12:23 pm
See Markman, 517 U.S. at 391; see also Amgen, Inc. v. [read post]
17 Oct 2011, 12:49 am
Overstock & Newegg.com (EDTexweblog.com) Amgen gets whacked in inter partes re-exam of US Pat. [read post]
12 Oct 2011, 11:56 am
Amgen, Inc. et al., No. 1:06-cv-10972-WGY, (D. [read post]
11 Oct 2011, 1:49 pm
The petitions of the day are: Amgen Inc. v. [read post]
11 Oct 2011, 4:56 am
Maxygen, Inc. brought an inter partes re-examination of Amgen's U.S. [read post]
16 Sep 2011, 11:02 am
The state has already settled cases with Astra Zeneca, Abbott Laboratories, GlaxoSmithKline, Amgen Inc., Baxter Healthcare Corp., Boehringer Ingelhelm Roxane, and Dey Pharmaceutical and has prevailed at trial against Johnson & Johnson and Bristol-Meyers Squibb. [read post]
25 Aug 2011, 7:01 am
Amgen, Inc., No. 2:11-cv-00553, slip op. [read post]
28 Jul 2011, 3:00 am
Distinct issues of construction arose in respect of claims 1 and 3 of the patent:Claim 1:A wound dressing comprising a blend of discrete modified cellulose gel forming fibres with at least one other type of discrete gel forming fibres.Claim 3:A wound dressing as claimed in any preceding claim wherein the dressing comprises a wound contacting surface consisting of a blend of discrete modified cellulose fibres with at least one other type of discrete gel forming fibres.Setting out the law, the Judge… [read post]
20 Jul 2011, 4:04 am
(Spicy IP) US: Multicell Technologies receives stem cell patent (Patent Docs) US: FDA’s NDI guidance and the 18-year cycle of correcting regulatory overreach (FDA Law Blog) Products Adenoscan (Adenosine) – US: Astellas settles Adenoscan patent suit with Sagent and Strides Arcolab (Patent Docs) Angiomax (Bivalirudin) – US: The MDCO PTE decision: In play on Capitol Hill and in action at the PTO (FDA Law Blog) Cipralex (Escitalopram) – Austria: SPCs and Escitalopram in… [read post]
7 Jul 2011, 1:42 pm
In In re Amgen, Inc., No. 10-MC-0249(SLT) (E.D.N.Y. [read post]
5 Jul 2011, 1:44 pm
…Call me Ishmael. [read post]
3 Jul 2011, 11:08 pm
Flood, Inc. [read post]
23 Jun 2011, 2:03 am
The overriding issue in the pre-grant opposition proceeding before Heerey J was whether it was practically certain that the patent to be granted on the specification would have been invalid on the ground that the content of the specification was not in accordance with the requirements of s 40 of the Patents Act 1952 (Cth) (Genetics Institute Inc v Kirin-Amgen Inc (No 3) (1998) 156 ALR 30 at 39-41). [read post]
8 Jun 2011, 5:00 am
Sugar, recently retired as the Chairman and CEO of Northrop Grumman and has also served as a director of Amgen Inc. and Chevron Corporation. [read post]
